Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

← catalyst calendar

NCT02016924

Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.

Phase

Phase 2/3

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

133actual

Sites

Countries

Argentina, South Africa, Thailand +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2014-01-16

actual

When the study began enrolling

Primary completion

2025-06-13

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2027

estimated

The whole study's end, after follow-up

First posted

2013-12-20

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-21

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Acquired Immune Deficiency Syndrome (AIDS)
HIV Infections

Interventions

Drug: ATV — also filed as Reyataz®
Drug: DRV — also filed as Prezista®
Drug: Cobicistat — also filed as GS-9350, Tybost®
Drug: BR
Drug: F/TAF — also filed as Descovy®
Drug: LPV/r
Drug: Third Unboosted Drug
Drug: Cobicistat TOS — also filed as GS-9350, Tybost®
Drug: F/TAF TOS — also filed as Descovy®

Primary outcomes

what the primary-completion date above is the date OF

Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, TAF, and TFV

measured Predose on Day 1, and postdose up to Week 48

Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) Through Week 24

measured First dose date up to Week 24 plus 30 days (Cumulative data through Week 24)

Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities Through Week 24

measured First dose date up to Week 24 plus 30 days (Cumulative data through Week 24)

Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed